N-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxo-pentan-2-yl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-tert-butoxy-ethyl]carbamoyl]-2-(4-hydroxyphenyl)
ethyl]carbamoyl]-2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-pyrrolidine-2-carboxamide

Absorption
T max for the 3.6 mg implant is 12 to 15 days in men and 8 to 22 days in women. T max for the 10.8 mg implant is 2 h in men. C max for the 3.6 mg implant is about 1.46 ng/mL in women and 2.84 ng/mL in men and for the 10.8 mg is about 8 ng/mL in men.

Distribution
Vd is 44.1 L in men and 20.3 L in women. Protein binding is 27%.

Metabolism
Hydrolysis of the C-terminal amino acids.

Elimination
The t 1/ 2 for the 3.6 mg implant is 4.2 h in men and 2.3 h in women. More than 90% is excreted in urine, 20% unchanged. Mean systemic Cl for the 3.6 mg implant is 111 mL/min in men and to 164 mL/min in women.

Onset
1 wk.

Peak
2 to 4 wk.

Special Populations
Renal Function Impairment
In CrCl less than 20 mL/min, the t 1/ 2 is 12.1 h.

Increased body weight
A decline in AUC of about 1% to 2.5% was observed with a kg increase in body weight.